Therapeutic Advances in Drug Safety

Impact Factor: 3.4

Editor-In-Chief: Arduino Mangoni

Discipline: Pharmacology, Toxicology

Description:

Journal HighlightsLaunched in 2010.Gold open access journal – all articles are made freely available online immediately upon publication.Rigorous peer review.Listed in PubMed and indexed in Clarivate Analytics: Science Citation Index Expanded (SCIE), Scopus, and International Pharmaceutical Abstracts (ProQuest).Over 220,000 full article views annually.Therapeutic Advances in Drug Safety is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of drug safety. Please see the Aims and Scope tab for further information.The journal is a member of the Committee on Publication Ethics (COPE).Diversity, Equity and Inclusion StatementTherapeutic Advances in Drug Safety (TADS) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the drug safety community.Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms. Submission informationSubmit your manuscript today at http://mc.manuscriptcentral.com/tads.Please see the Submission Guidelines tab for more information on how to submit your article to the journal.Open access informationThe article processing charge (APC) for this journal is currently $3000 USD. The APC for a Plain Language Summary is $5000.The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.ContactPlease direct any enquiries to tads@sagepub.co.uk.This journal changed its publication mode from subscription to open access in 2019.